A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
Part of paid clinical trials in Bakersfield, California.
- Sponsor
- Amneal Pharmaceuticals, LLC
- Study ID
- NCT06267274
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Ocular Hypertension
- Open-angle Glaucoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Bimatoprost Ophthalmic Solution, 0.01% — DRUG1 drop of ophthalmic solution instill in both eyes every night at 10:00 pm (±1 hours) for 42 days (6 weeks) (± 4 days) as per the randomization schedule.
- LUMIGAN® (bimatoprost ophthalmic solution) 0.01% — DRUG1 drop of ophthalmic solution instill in both eyes every night at 10:00 pm (±1 hours) for 42 days (6 weeks) (± 4 days) as per the randomization schedule.
Study Details
A randomized, double-blind, parallel-group, two-arm, multiple dose, multicenter, clinical endpoint bioequivalence study
Key Dates
- Start date
- Apr 1, 2024
- Status verified
- Aug 2024
- Primary completion
- Mar 1, 2025
- Completion
- May 1, 2025
Study Design
- Enrollment
- 240 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Bimatoprost Ophthalmic Solution, 0.01%Test Product: Bimatoprost Ophthalmic Solution, 0.01%
- Active Comparator: LUMIGAN® (bimatoprost ophthalmic solution) 0.01%Reference Product: LUMIGAN® (bimatoprost ophthalmic solution) 0.01%
Primary Outcome Measure
Primary Endpoint [ Time Frame: 00.00 hour, 04.00 hours (4 hours ±1 hour after 00.00 hour), and 08.00 hours (8 hours ±1 hour after 00.00 hour) at Day 14 (Week 2) (± 4 days) and Day 42 (Week 6) (± 4 days) visits ]
Central Contacts
- Ilesh Changela, MD+91-79-67778300
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| West Coast Eye Institute | Bakersfield | California | 93308 | Sandeep Walia, MD |
| Eye Research Foundation | Newport Beach | California | 92663 | David Wirta, MD |
| Clayton Eye Research | Morrow | Georgia | 30260 | Kim Jong, MD |
| Houston Eye Associates | Houston | Texas | 77008 | Kevin Jong, MD |
Find similar trials in Bakersfield, CA
By condition
By specialty
Related Studies
- Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.PHASE3 · Recruiting · Amneal Pharmaceuticals, LLC · Newport Beach, California
- Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority TrialRecruiting · 59th Medical Wing · Lackland Air Force Base, Texas
- Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular HypertensionPHASE2 · Recruiting · PolyActiva Pty Ltd · Newport Beach, California
- Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)PHASE3 · Recruiting · SpyGlass Pharma, Inc. · Houston, Texas